Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telemedicine for Hepatitis C Monitoring in Brazil
NCT04039698Unknown
- Sponsor
- Hospital de Clínicas de Porto Alegre
- Start
- Aug 2019
- Primary completion
- Dec 2020
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label, single-arm trial of velpatasvir in hepatitis C (HCV), sponsored by Hospital de Clínicas de Porto Alegre. Primary endpoint: Sustained Virologic Response at 24 weeks. Status: unknown.
02
Drugs
velpatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT04039698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04039698.